Trade Collegium Pharmaceutical Inc - COLL CFD

Collegium Pharmaceutical Company profile

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on pain management. The Company's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone, and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate in adults.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Collegium Pharmaceutical Inc revenues decreased 11% to $276.9M. Net income increased from $26.8M to $71.5M. Revenues reflect Xtampza segment decrease of 19% to $103.7M, Nucynta segment decrease of 5% to $173.2M. Net income reflects Interest expense decrease of 27% to $21M (expense), Advertising Expense decrease of 22% to $4.2M (expense).